TY  - JOUR
A1  - Schulmeyer, Carla E.
A1  - Fasching, Peter A.
A1  - Häberle, Lothar
A1  - Meyer, Julia
A1  - Schneider, Michael
A1  - Wachter, David
A1  - Ruebner, Matthias
A1  - Pöschke, Patrik
A1  - Beckmann, Matthias W.
A1  - Hartmann, Arndt
A1  - Erber, Ramona
A1  - Gass, Paul
T1  - Expression of the immunohistochemical markers CK5, CD117, and EGFR in molecular subtypes of breast cancer correlated with prognosis
JF  - Diagnostics
N2  - Molecular-based subclassifications of breast cancer are important for identifying treatment options and stratifying the prognosis in breast cancer. This study aimed to assess the prognosis relative to disease-free survival (DFS) and overall survival (OS) in patients with triple-negative breast cancer (TNBC) and other subtypes, using a biomarker panel including cytokeratin 5 (CK5), cluster of differentiation 117 (CD117), and epidermal growth factor receptor (EGFR). This cohort–case study included histologically confirmed breast carcinomas as cohort arm. From a total of 894 patients, 572 patients with early breast cancer, sufficient clinical data, and archived tumor tissue were included. Using the immunohistochemical markers CK5, CD117, and EGFR, two subgroups were formed: one with all three biomarkers negative (TBN) and one with at least one of those three biomarkers positive (non-TBN). There were significant differences between the two biomarker subgroups (TBN versus non-TBN) in TNBC for DFS (p = 0.04) and OS (p = 0.02), with higher survival rates (DFS and OS) in the non-TBN subgroup. In this study, we found the non-TBN subgroup of TNBC lesions with at least one positive biomarker of CK5, CD117, and/or EGFR, to be associated with longer DFS and OS.
KW  - early breast cancer
KW  - therapy
KW  - prognosis
KW  - CK5
KW  - CD117
KW  - EGFR
KW  - triple-negative breast cancer
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-304987
SN  - 2075-4418
VL  - 13
IS  - 3
ER  -